+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Healthcare Licensing Trends: Japan-Oncology

  • ID: 4861796
  • Report
  • September 2019
  • Region: Global
  • 57 pages
  • FinGlobe, Inc

FEATURED COMPANIES

  • Astellas Pharma Inc.
  • Eisai Co. Ltd.
  • Kagoshima University
  • Nichirei Bioscience Inc
  • Sanofi K.K.
  • Thyas Co. Ltd.

This trends report provides comprehensive analysis on all licensing deals and negotiations reported for the healthcare companies of Japan in the Oncology medicine group during January 1, 2019 to August 31, 2019, categorized and summarized by various important aspects such as healthcare sub-sectors, market capitalization groups, across key regions, licensing payment arrangements, and worldwide vs domestic licensing. Such detailed analysis helps to understand the licensing trends and directions during this time period in the healthcare segments of Japan for the Oncology medicine group.

Analytical data coverage:

  • January 1, 2019 to August 31, 2019 licensing deals and negotiations
  • 60 healthcare licensing news for Japanese companies (40+) in the Oncology medicine group
  • Small-mid-large cap companies covered - LargeCap (36%)
  • Listed and non-listed companies included
  • 4 healthcare sub-sectors covered - Pharmaceuticals (52%), Biotech (19%), Medical Devices (10%), Healthcare Services (19%)
  • 8+ variables analyzed

Key Features:

  • 8 months’ healthcare licensing transactions of Japan in the Oncology medicine group analyzed at one place
  • Small, medium and big multinational/non-multinational companies covered
  • Curated categorizations of licensing details
  • Licensing trends and directions summarized

The Report is useful to:

  • Healthcare companies of Japan planning to introduce products in other countries in the Oncology medicine group
  • Companies active in R&D and seeking new market base
  • Healthcare company executives of Japan negotiating licensing deals in the Oncology medicine group
  • Investors analyzing varied kinds of transaction options for licensing deals in Japan in the Oncology medicine group

Key analysis provided: January-August 2019

  • Total number of licensing deals signed by companies of Japan in the Oncology medicine group
  • Total number of companies/institutes of Japan involved in the licensing deals in the Oncology medicine group
  • Most licensing deals signed by companies of which sub-industry within healthcare sector in the Oncology medicine group
  • Most licensing deals signed by which market capitalization group’s companies in the Oncology medicine group
  • Licensing payment arrangements most followed in the licensing deals in the Oncology medicine group
  • Number of domestic and worldwide licensing in the Oncology medicine group
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Astellas Pharma Inc.
  • Eisai Co. Ltd.
  • Kagoshima University
  • Nichirei Bioscience Inc
  • Sanofi K.K.
  • Thyas Co. Ltd.
Introduction
Research Design

Chapter 1: Analysis of healthcare inventions of Japan in the Oncology medicine group licensed during last eight months
1.1 Healthcare sub-sectors with most licensing deals
1.2 Market capitalization groups with most licensing deals
1.3 Licensing payment arrangements most followed
1.4 Worldwide licensing vs domestic licensing

Chapter 2: Analysis of licensing deals of Japan in the Oncology medicine group by key attributes during last eight months
2.1 For each of the healthcare sub-sectors
2.2 For each of the marketcap groups
2.3 Across each of the regions

Chapter 3: Summary and conclusions

Appendices
Appendix 1 Healthcare inventions licensed for Japan in the Oncology medicine group during last eight months - By company name
Appendix 2 List of companies/institutes covered - By company name
Appendix 3 List of companies/institutes covered - By sub-industry and company name
Appendix 4 List of companies/institutes covered - By market capitalization group and company name
Appendix 5 List of non-listed companies covered - By country and company name
Appendix 6 List of not-for-profit groups covered - By country and institute name
Appendix 7 List of companies/institutes covered - By terms of payment and company name
Appendix 8 Licensing deals discontinued for Japan in the Oncology medicine group during last eight months
Note: Product cover images may vary from those shown
  • Astellas Pharma Inc.
  • Carna Biosciences, Inc.
  • Chiome Bioscience Inc.
  • Chugai Pharmaceutical Co. Ltd.
  • CYTLIMIC Inc
  • Daiichi Sankyo Co. Ltd.
  • Eisai Co. Ltd.
  • Falco Holdings Co. Ltd
  • Fujifilm Corporation
  • Innovation Center of NanoMedicine
  • iPS Academia Japan, Inc.
  • Janssen Pharmaceutical K.K
  • J-Pharma Co., Ltd
  • Kagoshima University
  • Konica Minolta, Inc.
  • Kyoto University
  • Maruishi Pharmaceutical Co., Ltd.
  • Mitsubishi Tanabe Pharma Corporation
  • Mundipharma K.K
  • National Cancer Center
  • National Cancer Center Japan
  • National Cancer Center Japan (The)
  • Nichi-Iko Pharmaceutical Co., Ltd.
  • Nichirei Bioscience Inc
  • Nippon Kayaku Co., Ltd.
  • Nippon Shinyaku, Co., Ltd.
  • Noile-Immune Biotech Inc.
  • Ohara Pharmaceutical Co., Ltd.
  • Oncolys BioPharma Inc.
  • Ono Pharmaceutical Co., Ltd.
  • PHC Holdings Corporation
  • Sanofi K.K.
  • Shionogi & Co. Ltd.
  • Solasia Pharma K.K.
  • Sosei Group Corporation
  • Takara Bio Inc
  • Takeda Pharmaceutical Company Limited
  • Thyas Co. Ltd.
  • Toyo Corporation
  • University of Tokyo
  • Yakult Honsha Co., Ltd
  • Zenyaku Kogyo Co., Ltd
Note: Product cover images may vary from those shown
Adroll
adroll